Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 65 results
Filters: First Letter Of Title is E  [Clear All Filters]
Found 65 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

E

Overton ET, Kitch D, Benson CA, et al. "Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death." Clin. Infect. Dis.. 2013;56(10):1471-9.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Nixon DE, Bosch RJ, Chan ES, et al. "Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5." J Clin Lipidol. 2017;11(1):61-69.
Smurzynski M, Wu K, Letendre S, et al. "Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort." AIDS. 2011;25(3):357-65.
Blackard JT, Kang M, Sherman KE, Koziel MJames, Peters MG, Chung RT. "Effects of HCV treatment on cytokine expression during HCV/HIV coinfection." J. Interferon Cytokine Res.. 2006;26(11):834-8.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. "The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era." Antivir. Ther. (Lond.). 2009;14(4):543-9.
Mulligan K, Yang Y, Wininger DA, et al. "Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio." AIDS. 2007;21(1):47-57.
Bedimo R, Kang M, Tebas P, et al. "Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients." AIDS Res. Hum. Retroviruses. 2016;32(4):325-8.
Dubé MP, Parker RA, Mulligan K, et al. "Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384." Clin. Infect. Dis.. 2007;45(1):120-6.
Bhasin S, Parker RA, Sattler F, et al. "Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity." J. Clin. Endocrinol. Metab.. 2007;92(3):1049-57.
Campbell TB, Smeaton LM, Kumarasamy N, et al. "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings." PLoS Med.. 2012;9(8):e1001290.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Grant PM, Komarow L, Lederman MM, et al. "Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164." J. Infect. Dis.. 2012;206(11):1715-23.
Gallien S, Delaugerre C, Charreau I, et al. "Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia." AIDS. 2011;25(5):665-9.
Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
Labo N, Miley W, Benson CA, Campbell TB, Whitby D. "Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy." AIDS. 2015;29(10):1217-25.
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. "Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure." PLoS Pathog.. 2011;7(2):e1001303.
Schouten JThomas, Schiffer JT. "Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;60(1):68-71.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA. "Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095." J Am Stat Assoc. 2012;107(498):542-554.
Sattler FR, Rajicic N, Mulligan K, et al. "Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial." Am. J. Clin. Nutr.. 2008;88(5):1313-21.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Li B, Verma SS, Veturi YC, et al. "Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression." Pac Symp Biocomput. 2018;23:448-459.
Luetkemeyer AF, Kendall MA, Wu X, et al. "Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB." J. Clin. Microbiol.. 2014;52(4):1052-9.
Luetkemeyer AF, Firnhaber C, Kendall MA, et al. "Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings." Clin. Infect. Dis.. 2016;62(9):1081-8.
Jacobson JM, R Bucy P, Spritzler J, et al. "Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068." J. Infect. Dis.. 2006;194(5):623-32.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.
Manasa J, Varghese V, Pond SLKosakovs, et al. "Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors." Sci Rep. 2017;7(1):11559.

Pages